Bone metastasis in prostate cancer

被引：0

作者：

Moltzahn, F. ^{[1
]}

Thalmann, G. N. ^{[1
]}

机构：

[1] Inselspital Bern, Urol Univ Klin, CH-3010 Bern, Switzerland

来源：

UROLOGE | 2012年 / 51卷 / 01期

关键词：

Prostate cancer; Bone metastases; castration resistant; Bisphosphonates; Denosumab; ADVANCED BREAST-CANCER; LONG-TERM EFFICACY; ZOLEDRONIC ACID; SKELETAL COMPLICATIONS; DOUBLE-BLIND; PHASE-II; CELLS; BISPHOSPHONATES; PAMIDRONATE; SURVIVAL;

D O I：

10.1007/s00120-011-2741-1

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Bone metastasis and skeletal complications have a devastating impact on the quality of life and are a major cause of morbidity in prostate cancer patients. In addition to established bone-targeted therapies, new drugs such as endothelin A receptor antagonists, MET and VEGFR-2 antagonists or radiophar-maceuticals are in the focus of development. The standard care in prostate cancer patients with bone metastases to prevent skeletal-related events (SRE) are bisphosphonates. Denosumab, a human monoclonal antibody against RANKL, appeared to be superior to zoledronic acid for prevention of SRE and has been shown to prolong bone metastases-free survival. In contrast to zoledronic acid, denosumab clearance is not dependent on kidney function and can be administered subcutaneously. Similar rates of toxicity were observed for both substances; however, long-term data for denosumab are limited.

引用

页码：20 / +

页数：6

共 41 条

[1]

Bayer, 2011, ALPH SIGN IMPR OV SU

[2] Metastatic patterns of prostate cancer:: An autopsy study of 1,589 patients [J].

Bubendorf, L ;

Schöpfer, A ;

Wagner, U ;

Sauter, G ;

Moch, H ;

Willi, N ;

Gasser, TC ;

Mihatsch, MJ .

HUMAN PATHOLOGY, 2000, 31 (05) :578-583

[3] Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial [J].

Carducci, MA ;

Padley, RJ ;

Breul, J ;

Vogelzang, NJ ;

Zonnenberg, BA ;

Daliani, DD ;

Schulman, CC ;

Nabulsi, AA ;

Humerickhouse, RA ;

Weinberg, MA ;

Schmitt, JL ;

Nelson, JB .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :679-689

[4] A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer [J].

Carducci, Michael A. ;

Saad, Fred ;

Abrahamsson, Per-Anders ;

Dearnaley, David R. ;

Schulman, Claude C. ;

North, Scott A. ;

Sleep, Darryl J. ;

Isaacson, Jeffrey D. ;

Nelson, Joel B. .

CANCER, 2007, 110 (09) :1959-1966

[5] Bisphosphonates and cancer-induced bone disease:: Beyond their antiresorptive activity [J].

Clézardin, P ;

Ebetino, FH ;

Fournier, PGJ .

CANCER RESEARCH, 2005, 65 (12) :4971-4974

[6]

Clincial trials gov, 2008, RADAR TRIAL RAND AND

[7] Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial [J].

Conte, PF ;

Latreille, J ;

Mauriac, L ;

Calabresi, F ;

Santos, R ;

Campos, D ;

Bonneterre, J ;

Francini, G ;

Ford, JM .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (09) :2552-2559

[8] Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer [J].

Cook, Richard J. ;

Coleman, Robert ;

Brown, Janet ;

Lipton, Allan ;

Major, Pierre ;

Hei, Yong Jiang ;

Saad, Fred ;

Smith, Matthew R. .

CLINICAL CANCER RESEARCH, 2006, 12 (11) :3361-3367

[9] Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation [J].

Coxon, JP ;

Oades, GM ;

Kirby, RS ;

Colston, KW .

BJU INTERNATIONAL, 2004, 94 (01) :164-170

[10] Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials [J].

Dearnaley, David P. ;

Mason, Malcolm D. ;

Parmar, Mahesh K. B. ;

Sanders, Karen ;

Sydes, Matthew R. .

LANCET ONCOLOGY, 2009, 10 (09) :872-876

← 1 2 3 4 5 →